Inhibition of phosphodiesterase type 3 dilates the rat ductus arteriosus without inducing intimal thicknening

DOI Web Site PubMed 被引用文献5件 参考文献36件

書誌事項

タイトル別名
  • Inhibition of Phosphodiesterase Type 3 Dilates the Rat Ductus Arteriosus Without Inducing Intimal Thickening

この論文をさがす

説明

Background: Prostaglandin E1 (PGE1), via cAMP, dilates the ductus arteriosus (DA). For patients with DA-dependent congenital heart disease (CHD), PGE1 is the sole DA dilator that is used until surgery, but PGE1 has a short duration of action, and frequently induces apnea. Most importantly, PGE1 increases hyaluronan (HA) production, leading to intimal thickening (IT) and eventually DA stenosis after long-term use. The purpose of this study was therefore to investigate potential DA dilators, such as phosphodiesterase 3 (PDE3) inhibitors, as alternatives to PGE1. Methods and Results: Expression of PDE3a and PDE3b mRNAs in rat DA tissue was higher than in the pulmonary artery. I.p. milrinone (10 or 1mg/kg) or olprinone (5 or 0.5mg/kg) induced maximal dilatation of the DA lasting for up to 2h in rat neonates. In contrast, vasodilation induced by PGE1 (10μg/kg) was diminished within 2h. No respiratory distress was observed with milrinone or olprinone. Most important, milrinone did not induce HA production, cell migration, or proliferation when applied to cultured rat DA smooth muscle cells. Further, high expression of both PDE3a and PDE3b was demonstrated in the human DA tissue of CHD patients. Conclusions: Because PDE3 inhibitors induced longer-lasting vasodilation without causing apnea or HA-mediated IT, they may be good alternatives to PGE1 for patients with DA-dependent CHD.  (Circ J 2012; 76: 2456–2464)<br>

収録刊行物

  • Circulation Journal

    Circulation Journal 76 (10), 2456-2464, 2012

    一般社団法人 日本循環器学会

被引用文献 (5)*注記

もっと見る

参考文献 (36)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ